{"transactions":[{"id":1968226,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-03-06T21:28:50.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":107202,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 107,202 newly awarded RSUs, 62,448 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 89,512 shares of common stock. On March 2, 2023, 20,816 of Prior RSUs vested and 41,632 of Prior RSUs remained unvested."}],"balance_after":259162,"source":{"system":"sec-edgar","filing":"0001628280-23-006529","document":"wf-form4_167813811794255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023006529/wf-form4_167813811794255.xml","form_type":"4"}},{"id":2120842,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-11-09T21:05:21.000Z","date":"2022-11-07","kind":"purchase","acquired":true,"shares":30000,"price":5.16,"value":154800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.98 to $5.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":89512,"source":{"system":"sec-edgar","filing":"0001628280-22-029215","document":"wf-form4_166802789941411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022029215/wf-form4_166802789941411.xml","form_type":"4"}},{"id":2349617,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T21:13:20.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":106838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":106838,"derivative":{"exercise_price":12.01,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":106838},"source":{"system":"sec-edgar","filing":"0001628280-22-005130","document":"wf-form4_164642837303389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005130/wf-form4_164642837303389.xml","form_type":"4"}},{"id":2349616,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-03-04T21:13:20.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":62448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."}],"balance_after":62448,"derivative":{"underlying":"Common Shares","underlying_shares":62448},"source":{"system":"sec-edgar","filing":"0001628280-22-005130","document":"wf-form4_164642837303389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005130/wf-form4_164642837303389.xml","form_type":"4"}},{"id":2349615,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-03-04T21:13:20.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":4849,"price":12.01,"value":58236.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards."}],"balance_after":59512,"source":{"system":"sec-edgar","filing":"0001628280-22-005130","document":"wf-form4_164642837303389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005130/wf-form4_164642837303389.xml","form_type":"4"}},{"id":2349614,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-03-04T21:13:20.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 18, 2021, the Reporting Person was granted stock based performance awards (\"Performance Awards\") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration."}],"balance_after":64361,"source":{"system":"sec-edgar","filing":"0001628280-22-005130","document":"wf-form4_164642837303389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005130/wf-form4_164642837303389.xml","form_type":"4"}},{"id":2514294,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-11","kind":"exercise","acquired":false,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":27900,"derivative":{"exercise_price":18.38,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514293,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-11","kind":"sale","acquired":false,"shares":11000,"price":29.5,"value":324500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":55861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514292,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-11","kind":"sale","acquired":false,"shares":29000,"price":28.82,"value":835780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.60 to $29.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":66861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514291,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-11","kind":"exercise","acquired":true,"shares":29000,"price":18.38,"value":533020.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":95861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514290,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":10000,"price":30.55,"value":305500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":66861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514289,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":50000,"price":31.26,"value":1563000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":76861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2514288,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-11-12T21:18:12.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":50000,"price":30.17,"value":1508500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":126861,"source":{"system":"sec-edgar","filing":"0001628280-21-023169","document":"wf-form4_163675187710828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021023169/wf-form4_163675187710828.xml","form_type":"4"}},{"id":2525687,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-03T20:20:23.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001628280-21-021477","document":"wf-form4_163597080368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021021477/wf-form4_163597080368439.xml","form_type":"4"}},{"id":2525686,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:20:23.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":45000,"price":31.64,"value":1423800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.50 to $31.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-021477","document":"wf-form4_163597080368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021021477/wf-form4_163597080368439.xml","form_type":"4"}},{"id":2525685,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:20:23.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":45000,"price":3.2,"value":144000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":221861,"source":{"system":"sec-edgar","filing":"0001628280-21-021477","document":"wf-form4_163597080368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021021477/wf-form4_163597080368439.xml","form_type":"4"}},{"id":2561523,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":56900,"derivative":{"exercise_price":18.38,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561522,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to the option vest in twenty-four equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.06,"expiration_date":"2029-01-29","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561521,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.3,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561520,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-20","kind":"exercise","acquired":false,"shares":28500,"price":5.3,"value":151050.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":7500,"derivative":{"exercise_price":5.3,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561519,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":87500,"price":24.02,"value":2101750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.90 to $24.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561518,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":10000,"price":18.38,"value":183800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":264361,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561517,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":70000,"price":6.06,"value":424200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":254361,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561516,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":7500,"price":5.3,"value":39750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":184361,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561515,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":16000,"price":21.6,"value":345600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.56 to $21.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561514,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":12500,"price":21.71,"value":271375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.70 to $21.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":192861,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2561513,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:31:03.000Z","date":"2021-09-20","kind":"exercise","acquired":true,"shares":28500,"price":5.3,"value":151050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":205361,"source":{"system":"sec-edgar","filing":"0001628280-21-019048","document":"wf-form4_163234265014624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021019048/wf-form4_163234265014624.xml","form_type":"4"}},{"id":2567308,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-16T21:01:51.000Z","date":"2021-09-14","kind":"exercise","acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":36000,"derivative":{"exercise_price":5.3,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001628280-21-018782","document":"wf-form4_163182609831779.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018782/wf-form4_163182609831779.xml","form_type":"4"}},{"id":2567307,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-16T21:01:51.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":30000,"price":21.8,"value":654000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.75 to $21.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-018782","document":"wf-form4_163182609831779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018782/wf-form4_163182609831779.xml","form_type":"4"}},{"id":2567306,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-16T21:01:51.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":14000,"price":21.73,"value":304220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.71 to $21.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":206861,"source":{"system":"sec-edgar","filing":"0001628280-21-018782","document":"wf-form4_163182609831779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018782/wf-form4_163182609831779.xml","form_type":"4"}},{"id":2567305,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-16T21:01:51.000Z","date":"2021-09-14","kind":"exercise","acquired":true,"shares":44000,"price":5.3,"value":233200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":220861,"source":{"system":"sec-edgar","filing":"0001628280-21-018782","document":"wf-form4_163182609831779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018782/wf-form4_163182609831779.xml","form_type":"4"}},{"id":2570357,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-14","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date."}],"balance_after":45000,"derivative":{"exercise_price":3.2,"expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570356,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-14","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option vest in thirty-six equal monthly installments from the grant date."}],"balance_after":80000,"derivative":{"exercise_price":5.3,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570355,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-13","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date."}],"balance_after":125000,"derivative":{"exercise_price":5.3,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570354,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":90000,"price":21.1913,"value":1907217.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $21.00 to $21.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570353,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-14","kind":"exercise","acquired":true,"shares":45000,"price":3.2,"value":144000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":266861,"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570352,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-14","kind":"exercise","acquired":true,"shares":45000,"price":5.3,"value":238500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":221861,"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570351,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":25000,"price":19.8,"value":495000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.76 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2570350,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2021-09-14T22:16:31.000Z","date":"2021-09-13","kind":"exercise","acquired":true,"shares":25000,"price":5.3,"value":132500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":201861,"source":{"system":"sec-edgar","filing":"0001628280-21-018603","document":"wf-form4_163165777007172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018603/wf-form4_163165777007172.xml","form_type":"4"}},{"id":2575590,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-09-08T20:04:37.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":7500,"price":18.1,"value":135750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021."}],"balance_after":176861,"source":{"system":"sec-edgar","filing":"0001628280-21-018219","document":"wf-form4_163113146158608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021018219/wf-form4_163113146158608.xml","form_type":"4"}},{"id":2587722,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-08-27T20:09:15.000Z","date":"2021-08-26","kind":"sale","acquired":false,"shares":22500,"price":17.81,"value":400725.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $17.76 to $17.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":184361,"source":{"system":"sec-edgar","filing":"0001628280-21-017720","document":"wf-form4_163009494191302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021017720/wf-form4_163009494191302.xml","form_type":"4"}},{"id":2608085,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-08-10T20:09:16.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":5000,"price":16.01,"value":80050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":206861,"source":{"system":"sec-edgar","filing":"0001628280-21-016403","document":"wf-form4_162862613567685.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021016403/wf-form4_162862613567685.xml","form_type":"4"}},{"id":2621897,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-07-29T20:09:42.000Z","date":"2021-07-28","kind":"sale","acquired":false,"shares":5000,"price":13.86,"value":69300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":211861,"source":{"system":"sec-edgar","filing":"0001628280-21-014882","document":"wf-form4_162758934279152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021014882/wf-form4_162758934279152.xml","form_type":"4"}},{"id":2656766,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-06-23T20:06:09.000Z","date":"2021-06-22","kind":"sale","acquired":false,"shares":5000,"price":13.76,"value":68800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date."}],"balance_after":216861,"source":{"system":"sec-edgar","filing":"0001628280-21-012730","document":"wf-form4_162447875291749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021012730/wf-form4_162447875291749.xml","form_type":"4"}},{"id":2715833,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option Grant (right to buy)","published_at":"2021-05-12T20:30:18.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. The expiration date was extended as a result of the blackout period."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2021-03-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-010021","document":"wf-form4_162085139436066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021010021/wf-form4_162085139436066.xml","form_type":"4"}},{"id":2715832,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":115902,"kind":"person","name":"Martin Michael Robert","position":1,"cik":"0001837647","reported_name":"Martin Michael Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:30:18.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":20000,"price":3.02,"value":60400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":221861,"source":{"system":"sec-edgar","filing":"0001628280-21-010021","document":"wf-form4_162085139436066.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021010021/wf-form4_162085139436066.xml","form_type":"4"}}]}